These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33165864)

  • 1. Modeling Leukemia Stem Cells with Patient-Derived Induced Pluripotent Stem Cells.
    Deslauriers AG; Kotini AG; Papapetrou EP
    Methods Mol Biol; 2021; 2185():411-422. PubMed ID: 33165864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia.
    Kotini AG; Chang CJ; Chow A; Yuan H; Ho TC; Wang T; Vora S; Solovyov A; Husser C; Olszewska M; Teruya-Feldstein J; Perumal D; Klimek VM; Spyridonidis A; Rampal RK; Silverman L; Reddy EP; Papaemmanuil E; Parekh S; Greenbaum BD; Leslie CS; Kharas MG; Papapetrou EP
    Cell Stem Cell; 2017 Mar; 20(3):315-328.e7. PubMed ID: 28215825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.
    Sakurai M; Kunimoto H; Watanabe N; Fukuchi Y; Yuasa S; Yamazaki S; Nishimura T; Sadahira K; Fukuda K; Okano H; Nakauchi H; Morita Y; Matsumura I; Kudo K; Ito E; Ebihara Y; Tsuji K; Harada Y; Harada H; Okamoto S; Nakajima H
    Leukemia; 2014 Dec; 28(12):2344-54. PubMed ID: 24732596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief Report: Human Acute Myeloid Leukemia Reprogramming to Pluripotency Is a Rare Event and Selects for Patient Hematopoietic Cells Devoid of Leukemic Mutations.
    Lee JH; Salci KR; Reid JC; Orlando L; Tanasijevic B; Shapovalova Z; Bhatia M
    Stem Cells; 2017 Sep; 35(9):2095-2102. PubMed ID: 28758276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations.
    Salci KR; Lee JH; Laronde S; Dingwall S; Kushwah R; Fiebig-Comyn A; Leber B; Foley R; Dal Cin A; Bhatia M
    Stem Cells; 2015 Jun; 33(6):1839-49. PubMed ID: 25764124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling myeloid malignancies with patient-derived iPSCs.
    Papapetrou EP
    Exp Hematol; 2019 Mar; 71():77-84. PubMed ID: 30481543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cell of origin and the leukemia stem cell in acute myeloid leukemia.
    Chopra M; Bohlander SK
    Genes Chromosomes Cancer; 2019 Dec; 58(12):850-858. PubMed ID: 31471945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zeb1 modulates hematopoietic stem cell fates required for suppressing acute myeloid leukemia.
    Almotiri A; Alzahrani H; Menendez-Gonzalez JB; Abdelfattah A; Alotaibi B; Saleh L; Greene A; Georgiou M; Gibbs A; Alsayari A; Taha S; Thomas LA; Shah D; Edkins S; Giles P; Stemmler MP; Brabletz S; Brabletz T; Boyd AS; Siebzehnrubl FA; Rodrigues NP
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33108352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia.
    Gentner B; Pochert N; Rouhi A; Boccalatte F; Plati T; Berg T; Sun SM; Mah SM; Mirkovic-Hösle M; Ruschmann J; Muranyi A; Leierseder S; Argiropoulos B; Starczynowski DT; Karsan A; Heuser M; Hogge D; Camargo FD; Engelhardt S; Döhner H; Buske C; Jongen-Lavrencic M; Naldini L; Humphries RK; Kuchenbauer F
    Exp Hematol; 2015 Oct; 43(10):858-868.e7. PubMed ID: 26163797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential niche and Wnt requirements during acute myeloid leukemia progression.
    Lane SW; Wang YJ; Lo Celso C; Ragu C; Bullinger L; Sykes SM; Ferraro F; Shterental S; Lin CP; Gilliland DG; Scadden DT; Armstrong SA; Williams DA
    Blood; 2011 Sep; 118(10):2849-56. PubMed ID: 21765021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reprogramming of Acute Myeloid Leukemia Patients Cells: Harboring Cancer Mutations Requires Targeting of AML Hierarchy.
    Golubeva D; Porras DP; Doyle M; Reid JC; Tanasijevic B; Boyd AL; Vojnits K; Elrafie A; Qiao A; Bhatia M
    Stem Cells Transl Med; 2023 Jun; 12(6):334-354. PubMed ID: 37226319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in expression and function of LEF1 isoforms in normal versus leukemic hematopoiesis.
    Feder K; Edmaier-Schröger K; Rawat VPS; Kirsten N; Metzeler K; Kraus JM; Döhner K; Döhner H; Kestler HA; Feuring-Buske M; Buske C
    Leukemia; 2020 Apr; 34(4):1027-1037. PubMed ID: 31758089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem Cells.
    Wesely J; Kotini AG; Izzo F; Luo H; Yuan H; Sun J; Georgomanoli M; Zviran A; Deslauriers AG; Dusaj N; Nimer SD; Leslie C; Landau DA; Kharas MG; Papapetrou EP
    Cell Rep; 2020 Jun; 31(9):107688. PubMed ID: 32492433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The leukemic stem cell niche: current concepts and therapeutic opportunities.
    Lane SW; Scadden DT; Gilliland DG
    Blood; 2009 Aug; 114(6):1150-7. PubMed ID: 19401558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIM-3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways.
    Kikushige Y
    Cancer Sci; 2021 Sep; 112(9):3419-3426. PubMed ID: 34159709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia.
    Majeti R
    Best Pract Res Clin Haematol; 2014; 27(3-4):229-34. PubMed ID: 25455271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell.
    Shima T; Miyamoto T; Kikushige Y; Yuda J; Tochigi T; Yoshimoto G; Kato K; Takenaka K; Iwasaki H; Mizuno S; Goto N; Akashi K
    Exp Hematol; 2014 Nov; 42(11):955-65.e1-5. PubMed ID: 25101977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling of hematologic malignancies by iPS technology.
    Arai S; Miyauchi M; Kurokawa M
    Exp Hematol; 2015 Aug; 43(8):654-60. PubMed ID: 26135030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.
    Terwijn M; Zeijlemaker W; Kelder A; Rutten AP; Snel AN; Scholten WJ; Pabst T; Verhoef G; Löwenberg B; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    PLoS One; 2014; 9(9):e107587. PubMed ID: 25244440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.